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The ﬁeld of acute coronary syndromes (ACS) is rapidly
changing. Besides new drugs, the evolution is mainly driven
by the introduction of novel biomarkers in an effort to
respond to the partly unmet need for better diagnosis, prog-
nostication, and management of patients. Novel biomarkers
may improve diagnostic accuracy, identify subgroups of pa-
tients who may beneﬁt from a speciﬁc therapeutic modality
in the acute phase, and reveal pathophysiological insights
that need to be addressed by long-term medical treatment.
In this context, the new-generation cardiac troponin (cTn)
assays provide considerably more sensitive and timely
diagnosis of ACS (1), whereas their combination with
C-terminal provasopressin (copeptin) further enhances
diagnostic accuracy (2).
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The introduction of new biomarkers has undoubtedly
moved our approach several steps forward, but it also gave
rise to novel issues that need to be addressed by future
research. The highly sensitive new-generation cTn assays
modify the classiﬁcation of patients with non–ST-segment
elevation acute coronary syndrome (NSTE-ACS) by in-
creasing the percentage of cases with NSTE myocardial
infarction and limiting that of unstable angina (Fig. 1). As a
result, this reclassiﬁcation creates a need for novel prog-
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sions. In particular, the long-term beneﬁt of an invasive
approach in the subgroup of patients who are reclassiﬁed
from unstable angina to NSTE myocardial infarction has
not yet been proven by large randomized trials. Whether
this need is addressed by novel biomarkers remains to be
seen (Fig. 1).
In this issue of the Journal, O’Malley et al. (3) report on
the prognostic signiﬁcance of copeptin, midregional pro-
adrenomedullin (MR-proADM), and midregional pro-
atrial natriuretic peptide (MR-proANP) in 4,432 patients
with moderate-risk or high-risk NSTE-ACS. Conﬁrming
the results of previous smaller studies (4–6), all 3 novel bio-
markers were independently associated with cardiovascular
death or heart failure at 1 year. Furthermore, the addition of
each of the 3 biomarkers to a predictive model consisting
of clinical variables and a constellation of established or
emerging biomarkers, including B-type natriuretic peptide
(BNP), cTnI, pregnancy-associated plasma protein-A
(PAPP-A), ST2, and myeloperoxidase (MPO), improved
the statistical indicators of prognostic performance (inte-
grated discrimination improvement and net reclassiﬁcation
improvement) for the same endpoint (3). In the same context,
another novel biomarker that is currently undergoing
rigorous research, growth differentiation factor 15, has been
shown to increase the predictive value of the GRACE
(Global Registry of Acute Coronary Events) score in patients
with NSTE-ACS (7). Thus, those and other new biomarkers
may help build novel prognostication models and treatment
algorithms that would perform better in the currently
evolving clinical setting. O’Malley et al. (3) used the previous-
generation cTnI, and one question that may arise from this
study is whether the results would have been the same if the
new-generation cTn had been used.
The prognostic value of markers of myocardial stress in
patients with ACS is not new knowledge. Natriuretic
peptides have been known to be independently associated
with prognosis in patients with ACS for nearly 2 decades
(8). This association, which existed even without elevation
of previous-generation cTn concentrations, was identiﬁed
across the whole spectrum of ACS and concerned death
and heart failure (9). Myocardial ischemia may cause
release of natriuretic peptides as a protective mechanism
against ischemia-induced hemodynamic changes, probably
through increased regional ventricular wall stress (9). Is-
chemia may trigger expression of natriuretic peptides even
independently of mechanical stress (10). Because ischemia
usually precedes myocardial necrosis, concentrations of
natriuretic peptides may increase even earlier than con-
centrations of troponins. However, evidence on the beneﬁt
of using natriuretic peptides in decision making for patients
with NSTE-ACS has hitherto been inconclusive (9). What
seems peculiar is that in the vast majority of studies on
ACS, natriuretic peptides predicted endpoints such as
mortality or heart failure, but not ischemic events, despite
that ischemia seems to be implicated in their elevation in
Figure 1 The Role of Biomarkers in the Diagnosis and Risk Stratiﬁcation of Patients With ACS
Therapeutic guidance to invasive (shaded red area) or medical therapy for patients with non–ST-segment elevation ACS classiﬁed into non–ST-segment elevation myocardial
infarction (non STEMI) and unstable angina (UA) by previous-generation cardiac troponins is offered by a number of variables. These include history, physical examination,
electrocardiogram, biomarkers (i.e., troponin, natriuretic peptides [NPs], interleukin [IL]-6, and growth differentiation factor [GDF]-15, and risk scores (such as Thrombolysis In
Myocardial Infarction [TIMI] and GRACE [Global Registry of Acute Coronary Events]). The new-generation cardiac troponins reclassify a number of patients from UA to NSTEMI
(shaded blue area). It is not yet known whether novel biomarkers may guide therapy in this particular subgroup of patients. ACS ¼ acute coronary syndrome(s); cTn ¼ cardiac
troponin; ECG ¼ electrocardiogram; NP ¼ natriuretic peptides; STEMI ¼ ST-segment elevation myocardial infarction; Tx ¼ therapy.
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1655ACS. This is also the case in the current study by O’Malley
et al. (3). Those ﬁndings may imply that there is a role for
natriuretic peptide–guided therapy with neurohormonal
inhibitors in NSTE-ACS, although data concerning this
approach remain conﬂicting (11,12).
Several additional issues have arisen regarding the
emerging biomarkers. For example, the pathophysiology
and clinical signiﬁcance of minor elevations in cTn con-
centrations are not completely known, particularly given that
cutoffs have been derived by healthy and relatively young
populations, and factors such as aging or renal dysfunction
may impair troponin release or clearance (13). Establish-
ment of cutoffs will also be required for the emerging bio-
markers on the basis of carefully selected study populations
(9). Furthermore, the cost effectiveness of management
strategies on the basis of the novel biomarkers should be
evaluated (14).
The robust statistical results provided by O’Malley
et al. (3) and several previous investigators do not translate
into clinical beneﬁt unless integrated into practical and cost-
effective management strategies that improve established
diagnostic and therapeutic approaches. This constitutes the
most signiﬁcant challenge that clinical research has to
address in the ﬁeld of biomarkers.
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